ClinicalTrials.gg
CompletedNCT04270045Updated Nov 13, 2026

Forced Oscillometry in Infants With Bronchopulmonary Dysplasia

An observational study in Infant, Premature, Diseases, Bronchopulmonary Dysplasia and Respiratory Distress Syndrome, sponsored by Winston Manimtim. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-13.

Primary conditionBronchopulmonary DysplasiaRegistry: Infant, Premature, DiseasesReclassifiedWhy we changed it
Registry
Infant, Premature, Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Bronchopulmonary Dysplasia
Why
  1. The study's listed conditions name Bronchopulmonary Dysplasia, a narrower term within Infant, Premature, Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Winston Manimtim · Observational

How we know

Updated Nov 13, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
44
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 147 studies in Bronchopulmonary Dysplasia with a site in United States — 29 open to participants now, 36 under way, 1 of them phase 3. Bronchopulmonary Dysplasia · United States.

Enrollment
24th of 30
44 · median 155
Started
2019
with 9 others
Observational
30 of 147
7 open now
Registered
100th of 147
by date

Among the 147 studies in Bronchopulmonary Dysplasia with a site in United States, this one is the 24th largest by enrollment of the 30 observational ones that give a count, is one of 10 that started in 2019, is one of 30 observational ones, and was the 100th registered.

Bronchopulmonary Dysplasia

363 studies on the registry are indexed under Bronchopulmonary Dysplasia; 85 are open to participants now.

Browse Bronchopulmonary Dysplasia studies →

Open to participants now

29 of the 147 studies in Bronchopulmonary Dysplasia with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Bronchopulmonary Dysplasia studies recruiting now, 6 (11%) set no upper age limit and 50 (88%) stop at 75 or younger; 55 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Bronchopulmonary Dysplasia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to use forced oscillometry technique (FOT) to measure pulmonary mechanics and function in in term infants and premature infants with bronchopulmonary dysplasia (BPD)

Read the detailed description

Pulmonary function testing has been the standard of care to diagnose and evaluate response to therapy in various respiratory diseases in adults and children. There are several equipment and techniques that are FDA approved for these purposes. However, there are currently no lung function tests that are practically feasible, clinically meaningful and widely used in infants.

The forced oscillation technique (FOT) is a non-invasive method that had been used to measure respiratory mechanics. FOT employs small amplitude pressure oscillations superimposed on the normal breathing and therefore has the advantage over conventional lung function techniques that it does not require the performance of respiratory maneuvers. To date, the use of this technique is FDA approved in adults and children but remains largely experimental in infants and newborns. THORASYS has recently developed a new respiratory function test device aimed specifically at newborn and infants (0 - 2 years age group) called tremoflo N-100 ("Neo"). This new device measures lung function in only a few minutes while the newborn or infant is sleeping normally. It uses an adapted version of the Airwave Oscillometry (AOS) to calculate the impedance of the lungs and quantify airway obstruction.

Diuretics and bronchodilators are two on the most commonly used medications to ameliorate the symptoms of BPD. The benefits of these therapies have not been shown to prevent the development of BPD in a randomized control trial (RCT). More recently, there have been some evidence from pharmacogenetic studies that the variability in bronchodilator responsiveness in patients with asthma, (and possibly BPD) may lie on the gene encoding the B2-adrenergic receptor (ADRB2) as well as within the associated G-protein receptor pathway, the nitric oxide biosynthetic pathway and other novel loci identified in recent genome-wide studies. This part of the study will be hypothesis generating to try to understand the variability in bronchodilator response in infants with BPD. Normative data will be established in term neonates.

03

Conditions studied

  • Infant, Premature, Diseases
  • Bronchopulmonary Dysplasia
  • Respiratory Distress Syndrome
04

In context

Bronchopulmonary Dysplasia Reclassified

363 studies on the registry are indexed under Bronchopulmonary Dysplasia; 85 are open to participants now.

This study's enrollment of 44 is below the median of 150 across 100 observational studies indexed under Bronchopulmonary Dysplasia.

Browse Bronchopulmonary Dysplasia studies →

Lead sponsor

This is the only study on the registry with Winston Manimtim as lead sponsor.

Compared within Bronchopulmonary Dysplasia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infant, Premature, Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Premature infants with bronchopulmonary Dysplasia who are in room air or Premature infants with BPD who are receiving low flow O2 support and able to maintain normal spO2 in Room air for brief period (up to 3 minutes) Term infants without pulmonary disease. Former preterm infants (\<32 weeks) with BPD seen prior to 2 years of age in the outpatient setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Preterm Cohort:

  • Premature infants with BPD who are in room air based on the (per NICHD definition)
  • Premature infants with BPD who are receiving low flow O2 support and able to maintain normal spO2 in Room air for brief period ( up to 3 minutes) Term Cohort without pulmonary disease
  • Infants >36 weeks gestational age without pulmonary disease
  • Infants \< 4 weeks of age

Outpatient Cohort:

  • Former preterm infants \< 32 weeks at birth
  • Those with BPD based on NIH 2001 definition
  • Seen prior to 2 years of age

Exclusion criteria

Exclusion Criteria:

  • Infants with BPD requiring invasive or non-invasive positive pressure ventilation
  • Infants with BPD who have associated genetic diagnosis or major congenital anomalies.
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
44 participants (actual)
Patient registry
No

Groups and cohorts

  • Single

    Non-invasive forced airway oscillometry. Normative data will be established form term neonates without pulmonary disease

    Device: Non-invasive forced airway oscillometry

Interventions

  • DeviceNon-invasive forced airway oscillometry

    This non-invasive device will measure pulmonary mechanics in spontaneously breathing premature infants and term infants without pulmonary disease. Infant will be in supine position and breathing regularly. A cushioned mask will be placed on the infant's face, covering the nose and mouth. Measurements typically take less than 20 seconds and no more than 3 repetitions will be done at each time point.

07

What researchers measure

Primary outcomes

  1. Forced oscillation technique measurements

    Baseline FOT measurements in premature infants with BPD and term infants without pulmonary disease.

    Time frame: FOT measurement prior to bronchodilator therapy

  2. Post-bronchodilator forced oscillation technique measurements (in subjects already receiving this therapy)

    FOT measurements in premature infants with BPD following bronchodilator therapy.

    Time frame: FOT measurement 30 to 60minutes following bronchodilator therapy

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Aug 2026, 82 months.

Of 47 non-industry observational studies under Bronchopulmonary Dysplasia, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's 82 months is above that.

Counting every sponsor, half of 49 studies reached it within 56 months; a quarter within 19 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Feb 2020 → Oct 2019, primary completion Sep 2027 → Aug 2026 and completion Dec 2027 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2020
First posted
Feb 17, 2020
StartActual
Oct 10, 2019was Feb 2020
Primary completionActual
Aug 20, 2026was Sep 2027
CompletionActual
Aug 20, 2026was Dec 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 13, 2026
Start date
Feb 6, 2020→Oct 10, 2019
Nov 13, 2026
Primary completion
Sep 2027→Aug 20, 2026 (actual)
Nov 13, 2026
Study completion
Dec 31, 2027→Aug 20, 2026 (actual)
Nov 13, 2026
Enrollment
80 (estimated)→44 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Completed
    Start date Feb 6, 2020→Oct 10, 2019
    Primary completion Sep 2027→Aug 20, 2026 (now actual)
    Study completion Dec 31, 2027→Aug 20, 2026 (now actual)
    Enrollment 80 (estimated)→44 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04270045
Lead sponsor
Winston Manimtim
Responsible party
Winston Manimtim (Principal Investigator, Children's Mercy Hospital Kansas City) — Sponsor-investigator
First posted
Feb 17, 2020
Start date
Oct 10, 2019
Primary completion
Aug 20, 2026
Completion
Aug 20, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion